BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 9:54:00 AM | Browse: 1029 | Download: 968
Publication Name World Journal of Gastroenterology
Manuscript ID 5818
Country/Territory United States
Received
2013-09-27 06:52
Peer-Review Started
2013-09-27 11:57
To Make the First Decision
2013-10-14 21:10
Return for Revision
2013-12-02 10:06
Revised
2014-02-08 05:14
Second Decision
2014-02-20 15:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-20 16:05
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-04-23 10:19
Publish the Manuscript Online
2014-05-14 10:58
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand?
Manuscript Source Invited Manuscript
All Author List Masato Fujiki, Federico Aucejo, Minsig Choi and Richard Kim
Funding Agency and Grant Number
Corresponding Author Richard Kim, MD, Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Drive FOB-2, Tampa, FL 33612, United States. richard.kim@moffitt.org
Key Words Bridging therapy; Neo-adjuvant therapy; Locoregional therapy; Intermediate stage; Living donor liver transplantation; Ablation; Transarterial chemotherapy; Transarterial radioembolization; External beam radiotherapy
Core Tip Transarterial chemoembolization (TACE) and radiofrequency ablation are effective in down-staging intermediate staged hepatocellular carcinoma (HCC) to fulfill Milan criteria for liver transplantation (LT). New techniques using drug eluting beads-TACE, transarterial radioembolization and stereotactic radiation therapy have shown promising results in the treatment for advanced HCC over conventional TACE. In current practice, use of multimodality approach, taking advantage of the benefits of different locoregional therapy for HCC have been adopted as down-staging and bridging therapy for LT. Use of mandatory observation period prior to LT can exclude highly aggressive liver cancer that might not benefit from LT.
Publish Date 2014-05-14 10:58
Citation Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand? World J Gastroenterol 2014; 20(18): 5308-5319
URL http://www.wjgnet.com/1007-9327/full/v20/i18/5308.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i18.5308
Full Article (PDF) WJG-20-5308.pdf
Full Article (Word) WJG-20-5308.doc
Manuscript File 5818-Review.doc
Answering Reviewers 5818-Answering reviewers.pdf
Copyright License Agreement 5818-Copyright assignment.pdf
Peer-review Report 5818-Peer reviews.pdf
Scientific Editor Work List 5818-Scientific editor work list.doc